Hub : Traits :

Medication: Atorvastatin

56 significantly associated models · 27 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 108854166 110733794 6 1 3.8e-29 6.6e-29 1.0e+00 100 PSRC1
2 2 20529948 21958745 1 1 4.7e-12 2.1e-12 1.0e+00 100 APOB
3 2 26854065 28414302 5 1 2.1e-14 3.1e-14 1.0e+00 100 FNDC4
4 5 73969058 75594743 4 1 1.0e-14 2.1e-12 7.5e-01 100 HMGCR
5 9 21303958 22705094 1 1 2.7e-07 9.2e-10 1.4e-04 61 CDKN2B
6 11 115953897 117745003 3 4 4.0e-20 1.3e-22 2.0e-07 72 BUD13 PAFAH1B2 ZNF259
7 19 10377885 12191233 4 3 1.7e-09 2.4e-29 9.8e-18 42 EPOR KANK2 SPC24
8 19 44704753 46098885 2 2 3.9e-08 4.9e-36 1.2e-28 22 PVRL2 TOMM40

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.83 1 0 0.0 0.00 1.0e+00 FNDC4
Schizophrenia vs Biploar Disorder 1.44 1 0 0.0 0.00 1.0e+00 FNDC4
Alzheimer’s Disease (in mother) 10.08 2 2 4.4 0.00 1.0e+00 PVRL2 TOMM40
Alzheimer’s Disease (in father) 4.50 2 1 2.2 0.00 1.0e+00 PVRL2 TOMM40
Alzheimer’s Disease (including proxy) 19.19 2 2 4.4 0.00 1.0e+00 PVRL2 TOMM40
Crohns Disease (2017) 2.08 1 1 2.2 0.00 1.0e+00 FNDC4
Irritable Bowel Disease (IBD) 1.71 1 1 2.2 0.00 1.0e+00 FNDC4
Breast Cancer 1.61 1 0 0.0 0.00 1.0e+00 CDKN2B
Body Mass Index (BMI) (2010) 1.65 1 0 0.0 0.00 1.0e+00 HMGCR
Coronary Artery Disease (CAD) 17.23 5 3 6.7 0.94 5.1e-03 BUD13 CDKN2B EPOR PSRC1 ZNF259
Crohns Disease (2012) 0.96 1 0 0.0 0.00 1.0e+00 FNDC4
Fasting Glucose 7.78 1 1 2.2 0.00 1.0e+00 FNDC4
HDL Cholesterol 22.84 6 3 6.7 -0.67 9.7e-02 APOB BUD13 PSRC1 PVRL2 TOMM40 ZNF259
LDL Cholesterol 121.82 12 11 24.4 0.88 7.1e-05 APOB BUD13 EPOR FNDC4 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Primary Biliary Cirrhosis 2.16 2 0 0.0 0.00 1.0e+00 EPOR FNDC4
Rheumatoid Arthritis 1.71 1 0 0.0 0.00 1.0e+00 KANK2
Triglycerides 110.39 6 5 11.1 0.58 1.8e-01 APOB BUD13 FNDC4 PAFAH1B2 PVRL2 ZNF259
Type 2 Diabetes (T2D) (2012) 2.01 1 0 0.0 0.00 1.0e+00 CDKN2B
Ulcerative Colitis 1.38 1 0 0.0 0.00 1.0e+00 PAFAH1B2
Blood Eosinophil Count 2.55 5 3 6.7 -0.19 7.2e-01 BUD13 EPOR PAFAH1B2 TOMM40 ZNF259
Blood Platelet Count 6.49 8 6 13.3 -0.02 9.6e-01 BUD13 CDKN2B FNDC4 HMGCR PAFAH1B2 PVRL2 TOMM40 ZNF259
Blood Red Count 0.86 2 1 2.2 0.00 1.0e+00 FNDC4 PVRL2
Blood White Count 3.46 6 2 4.4 0.16 7.6e-01 CDKN2B EPOR FNDC4 KANK2 PAFAH1B2 PVRL2
Heel T-Score 0.79 4 0 0.0 -0.74 2.6e-01 APOB HMGCR PSRC1 TOMM40
BMI 2.33 3 2 4.4 0.00 1.0e+00 FNDC4 HMGCR KANK2
Height 1.74 7 5 11.1 -0.88 3.6e-03 EPOR FNDC4 KANK2 PSRC1 SPC24 TOMM40 ZNF259
Waist Hip Ratio (WHR) 0.87 1 0 0.0 0.00 1.0e+00 KANK2
Systolic Blood Pressure 1.41 4 0 0.0 0.99 6.9e-03 EPOR FNDC4 PAFAH1B2 TOMM40
Allergy or Eczema 1.53 2 0 0.0 0.00 1.0e+00 FNDC4 PVRL2
Cardiovascular Disease 13.79 11 11 24.4 0.99 4.0e-09 APOB BUD13 EPOR FNDC4 HMGCR PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Type 2 Diabetes (T2D) (2018) 4.05 1 1 2.2 0.00 1.0e+00 FNDC4
Lung FEV1/FVC ratio 1.03 1 1 2.2 0.00 1.0e+00 PSRC1
Lung FVC 0.87 2 0 0.0 0.00 1.0e+00 FNDC4 PVRL2
Hair Pigment 0.38 3 1 2.2 0.00 1.0e+00 CDKN2B EPOR FNDC4
Tanning 0.42 2 1 2.2 0.00 1.0e+00 EPOR FNDC4
Hand grip strength (left) 1.35 2 0 0.0 0.00 1.0e+00 FNDC4 PVRL2
Number of treatments/medications taken 4.64 2 0 0.0 0.00 1.0e+00 FNDC4 PSRC1
Relative age of first facial hair 1.96 1 1 2.2 0.00 1.0e+00 FNDC4
Systolic blood pressure, automated reading 0.81 1 0 0.0 0.00 1.0e+00 EPOR
Angina 12.37 3 2 4.4 0.00 1.0e+00 CDKN2B PSRC1 SPC24
Medication: Metformin 2.82 2 1 2.2 0.00 1.0e+00 CDKN2B FNDC4
Diabetes (father) 2.80 1 0 0.0 0.00 1.0e+00 FNDC4
Diabetes (mother) 2.94 2 0 0.0 0.00 1.0e+00 FNDC4 PVRL2
Impedance of leg (right) 2.23 2 2 4.4 0.00 1.0e+00 FNDC4 HMGCR
Leg fat-free mass (left) 3.59 5 2 4.4 -0.85 7.1e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Trunk fat percentage 1.37 2 1 2.2 0.00 1.0e+00 HMGCR PVRL2
Hand grip strength (right) 1.39 2 0 0.0 0.00 1.0e+00 FNDC4 PVRL2
Hayfever, allergic rhinitis or eczema 1.61 2 0 0.0 0.00 1.0e+00 FNDC4 PVRL2
Sitting height 1.69 3 1 2.2 0.00 1.0e+00 FNDC4 KANK2 SPC24
Body mass index (BMI) 2.08 3 1 2.2 0.00 1.0e+00 FNDC4 HMGCR PVRL2
Impedance of leg (left) 2.24 2 2 4.4 0.00 1.0e+00 FNDC4 HMGCR
Leg predicted mass (left) 3.59 5 2 4.4 -0.85 6.9e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Trunk fat mass 1.67 2 1 2.2 0.00 1.0e+00 HMGCR PVRL2
Waist circumference 1.87 3 1 2.2 0.00 1.0e+00 FNDC4 HMGCR PVRL2
Forced vital capacity (FVC) 1.02 2 0 0.0 0.00 1.0e+00 EPOR PVRL2
Heart attack 9.12 3 2 4.4 0.00 1.0e+00 CDKN2B PSRC1 SPC24
Diabetes (self-reported) 3.07 1 1 2.2 0.00 1.0e+00 FNDC4
Medication: Simvastatin 35.22 12 10 22.2 0.97 1.6e-08 APOB BUD13 CDKN2B EPOR FNDC4 HMGCR PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Weight 2.77 4 2 4.4 -0.99 1.4e-02 EPOR FNDC4 HMGCR PVRL2
Impedance of arm (right) 3.30 4 2 4.4 0.84 1.6e-01 CDKN2B FNDC4 HMGCR KANK2
Arm fat percentage (right) 1.45 2 1 2.2 0.00 1.0e+00 HMGCR PVRL2
Trunk fat-free mass 4.34 5 4 8.9 -0.84 7.3e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Hip circumference 2.11 3 2 4.4 0.00 1.0e+00 FNDC4 HMGCR PVRL2
Alcohol intake versus 10 years previously 2.91 1 1 2.2 0.00 1.0e+00 FNDC4
Father's age at death 4.07 2 0 0.0 0.00 1.0e+00 CDKN2B PSRC1
Forced expiratory volume in 1-second (FEV1) 1.21 2 0 0.0 0.00 1.0e+00 EPOR PVRL2
Pulse rate 3.28 1 1 2.2 0.00 1.0e+00 FNDC4
Mouth/teeth dental problems: Dentures 1.27 1 0 0.0 0.00 1.0e+00 FNDC4
Medication: Cholesterol lowering 46.53 13 11 24.4 0.99 7.3e-11 APOB BUD13 CDKN2B EPOR FNDC4 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Illnesses of mother 1.93 1 0 0.0 0.00 1.0e+00 CDKN2B
Forced expiratory volume in 1-second (FEV1), Best measure 1.28 2 0 0.0 0.00 1.0e+00 EPOR PVRL2
Impedance of arm (left) 3.38 3 2 4.4 0.00 1.0e+00 FNDC4 HMGCR KANK2
Arm fat mass (right) 2.03 3 1 2.2 0.00 1.0e+00 FNDC4 HMGCR PVRL2
Trunk predicted mass 4.37 5 4 8.9 -0.84 7.3e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Standing height 1.91 5 4 8.9 -0.91 3.0e-02 EPOR FNDC4 KANK2 PSRC1 SPC24
Birth weight of first child 1.53 1 0 0.0 0.00 1.0e+00 EPOR
Peak expiratory flow (PEF) 0.92 1 0 0.0 0.00 1.0e+00 EPOR
Medication for cholesterol, blood pressure or diabetes 17.60 11 6 13.3 -0.98 9.0e-09 APOB BUD13 EPOR FNDC4 HMGCR PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Glaucoma (self-reported) 3.91 1 1 2.2 0.00 1.0e+00 CDKN2B
Gout (self-reported) 8.47 1 1 2.2 0.00 1.0e+00 FNDC4
High blood pressure (siblings) 1.67 1 0 0.0 0.00 1.0e+00 FNDC4
Forced vital capacity (FVC), Best measure 1.20 2 0 0.0 0.00 1.0e+00 EPOR PVRL2
Body fat percentage 1.56 2 1 2.2 0.00 1.0e+00 HMGCR PVRL2
Leg fat percentage (right) 1.70 3 1 2.2 0.00 1.0e+00 HMGCR KANK2 PVRL2
Arm fat-free mass (right) 4.19 4 2 4.4 -0.81 1.9e-01 EPOR FNDC4 HMGCR PSRC1
Comparative body size at age 10 1.05 1 0 0.0 0.00 1.0e+00 FNDC4
Number of full brothers 1.66 1 0 0.0 0.00 1.0e+00 ZNF259
Qualifications: College or University degree 0.72 1 0 0.0 0.00 1.0e+00 BUD13
Angina (self-reported) 12.35 3 2 4.4 0.00 1.0e+00 CDKN2B PSRC1 SPC24
Medication: Allopurinol 6.69 1 1 2.2 0.00 1.0e+00 FNDC4
Heart disease (mother) 5.83 1 1 2.2 0.00 1.0e+00 CDKN2B
Whole body fat mass 1.82 3 1 2.2 0.00 1.0e+00 FNDC4 HMGCR PVRL2
Leg fat mass (right) 2.12 3 1 2.2 0.00 1.0e+00 FNDC4 HMGCR PVRL2
Arm predicted mass (right) 4.13 4 2 4.4 -0.81 1.9e-01 EPOR FNDC4 HMGCR PSRC1
Pulse rate, automated reading 4.24 3 1 2.2 0.00 1.0e+00 APOB FNDC4 KANK2
Alcohol intake frequency. 5.86 1 1 2.2 0.00 1.0e+00 FNDC4
Comparative height size at age 10 2.55 4 2 4.4 -0.90 9.6e-02 FNDC4 KANK2 PSRC1 SPC24
Chest pain or discomfort 1.43 1 0 0.0 0.00 1.0e+00 CDKN2B
Medication: Aspirin 9.32 5 2 4.4 0.97 5.4e-03 APOB CDKN2B EPOR PSRC1 SPC24
Illnesses of father: Heart disease 11.14 5 2 4.4 0.94 1.8e-02 CDKN2B EPOR FNDC4 PSRC1 SPC24
Forced expiratory volume in 1-second (FEV1), predicted 1.61 1 0 0.0 0.00 1.0e+00 EPOR
Whole body fat-free mass 4.19 5 3 6.7 -0.85 7.0e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Leg fat-free mass (right) 3.61 5 2 4.4 -0.86 6.5e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Arm fat percentage (left) 1.44 2 1 2.2 0.00 1.0e+00 HMGCR PVRL2
Long-standing illness, disability or infirmity 2.08 1 0 0.0 0.00 1.0e+00 CDKN2B
Diabetes diagnosed by doctor 3.41 1 1 2.2 0.00 1.0e+00 FNDC4
Medication for cholesterol 7.72 6 1 2.2 -0.98 7.2e-04 FNDC4 HMGCR PAFAH1B2 PSRC1 PVRL2 SPC24
Back pain experienced in last month 1.62 1 0 0.0 0.00 1.0e+00 APOB
Breast cancer (self-reported) 1.56 1 0 0.0 0.00 1.0e+00 CDKN2B
Osteoporosis (self-reported) 1.53 1 0 0.0 0.00 1.0e+00 FNDC4
Medication: Aspirin 9.27 4 2 4.4 0.97 2.8e-02 CDKN2B EPOR PSRC1 SPC24
Medication: Gliclazide 2.63 1 0 0.0 0.00 1.0e+00 FNDC4
Illnesses of father: None of the above (group 1) 3.81 1 1 2.2 0.00 1.0e+00 CDKN2B
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.26 1 0 0.0 0.00 1.0e+00 PVRL2
Whole body water mass 4.22 5 2 4.4 -0.84 7.4e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Leg predicted mass (right) 3.61 5 2 4.4 -0.85 6.5e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Arm fat mass (left) 1.99 3 1 2.2 0.00 1.0e+00 FNDC4 HMGCR PVRL2
Number of self-reported non-cancer illnesses 4.65 2 1 2.2 0.00 1.0e+00 FNDC4 PSRC1
Eye problems/disorders: Glaucoma 4.58 1 1 2.2 0.00 1.0e+00 CDKN2B
High cholesterol (Self-reported) 84.07 12 12 26.7 0.98 3.9e-09 APOB BUD13 EPOR FNDC4 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Basal metabolic rate 3.87 5 2 4.4 -0.85 6.9e-02 EPOR FNDC4 HMGCR PSRC1 SPC24
Leg fat percentage (left) 1.73 3 1 2.2 0.00 1.0e+00 HMGCR KANK2 PVRL2
Arm fat-free mass (left) 4.02 4 2 4.4 -0.81 1.9e-01 EPOR FNDC4 HMGCR PSRC1
Diastolic blood pressure, automated reading 1.17 1 0 0.0 0.00 1.0e+00 CDKN2B
Myopia 2.11 1 0 0.0 0.00 1.0e+00 KANK2
Cholesterol lowering medication 42.47 13 12 26.7 0.99 5.7e-11 APOB BUD13 CDKN2B EPOR FNDC4 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 SPC24 TOMM40 ZNF259
Pain experienced in last month 1.15 1 0 0.0 0.00 1.0e+00 APOB
Basal cell carcinoma (self-reported) 2.03 1 0 0.0 0.00 1.0e+00 CDKN2B
Heart attack/myocardial infarction (self-reported) 9.24 3 2 4.4 0.00 1.0e+00 CDKN2B PSRC1 SPC24
Heart disease (siblings) 5.05 2 0 0.0 0.00 1.0e+00 PSRC1 ZNF259
Impedance of whole body 3.12 3 2 4.4 0.00 1.0e+00 FNDC4 HMGCR PSRC1
Leg fat mass (left) 2.14 3 1 2.2 0.00 1.0e+00 FNDC4 HMGCR PVRL2
Arm predicted mass (left) 4.13 4 2 4.4 -0.82 1.8e-01 EPOR FNDC4 HMGCR PSRC1

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 1 0.029 1.2
GTEx Adipose Visceral Omentum 0 0.000 1.3
GTEx Adrenal Gland 0 0.000 1.2
GTEx Artery Aorta 0 0.000 1.3
GTEx Artery Coronary 0 0.000 1.2
GTEx Artery Tibial 0 0.000 1.3
GTEx Brain Caudate basal ganglia 0 0.000 1.1
GTEx Brain Cerebellar Hemisphere 0 0.000 1.3
GTEx Brain Cerebellum 0 0.000 1.3
GTEx Brain Cortex 0 0.000 1.2
GTEx Brain Frontal Cortex BA9 0 0.000 1.2
GTEx Brain Hippocampus 0 0.000 1.1
GTEx Brain Hypothalamus 0 0.000 1.2
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.1
GTEx Brain Putamen basal ganglia 0 0.000 1.1
GTEx Breast Mammary Tissue 0 0.000 1.2
GTEx Breast Mammary Tissue (Male) 0 0.000 1.2
GTEx Breast Mammary Tissue (Female) 0 0.000 1.2
GTEx Cells EBV-transformed lymphocytes 0 0.000 1.2
GTEx Cells Transformed fibroblasts 2 0.048 1.3
GTEx Colon Sigmoid 0 0.000 1.2
GTEx Colon Transverse 0 0.000 1.3
GTEx Esophagus Gastroesophageal Junction 0 0.000 1.2
GTEx Esophagus Mucosa 3 0.090 1.3
GTEx Esophagus Muscularis 1 0.031 1.2
GTEx Heart Atrial Appendage 0 0.000 1.2
GTEx Heart Left Ventricle 0 0.000 1.2
GTEx Liver 2 0.279 1.5
GTEx Lung 0 0.000 1.2
GTEx Muscle Skeletal 1 0.035 1.3
GTEx Nerve Tibial 0 0.000 1.2
GTEx Ovary 1 0.110 1.4
GTEx Pancreas 0 0.000 1.2
GTEx Pituitary 0 0.000 1.3
GTEx Prostate 0 0.000 1.2
GTEx Skin Not Sun Exposed Suprapubic 0 0.000 1.2
GTEx Skin Sun Exposed Lower leg 1 0.027 1.3
GTEx Small Intestine Terminal Ileum 0 0.000 1.2
GTEx Spleen 1 0.071 1.3
GTEx Stomach 0 0.000 1.3
GTEx Testis 2 0.063 1.2
GTEx Thyroid 2 0.050 1.3
GTEx Uterus 0 0.000 1.2
GTEx Vagina 1 0.157 1.2
GTEx Whole Blood 1 0.050 1.4
METSIM Adipose 1 0.022 1.2
NTR Blood 1 0.042 1.3
ROSMAP Brain Pre-frontal Cortex 2 0.046 1.3
YFS Blood 2 0.043 1.3
CommonMind Brain Pre-frontal Cortex 7 0.130 1.3
The Cancer Genome Atlas Bladder Urothelial Carcinoma 0 0.000 1.3
The Cancer Genome Atlas Breast Invasive Carcinoma 2 0.045 1.2
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 1 0.091 1.3
The Cancer Genome Atlas Colon Adenocarcinoma 2 0.097 1.3
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.2
The Cancer Genome Atlas Glioblastoma Multiforme 1 0.098 1.2
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 0 0.000 1.2
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 1 0.024 1.2
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 2 0.098 1.3
The Cancer Genome Atlas Brain Lower Grade Glioma 1 0.023 1.3
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 3 0.271 1.4
The Cancer Genome Atlas Lung Adenocarcinoma 0 0.000 1.2
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 1 0.040 1.2
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 3 0.188 1.2
The Cancer Genome Atlas Pancreatic Adenocarcinoma 0 0.000 1.2
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 0 0.000 1.2
The Cancer Genome Atlas Prostate Adenocarcinoma 2 0.043 1.3
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.3
The Cancer Genome Atlas Soft Tissue Sarcoma 1 0.094 1.2
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 1.2
The Cancer Genome Atlas Stomach Adenocarcinoma 2 0.119 1.2
The Cancer Genome Atlas Testicular Germ Cell Tumors 0 0.000 1.2
The Cancer Genome Atlas Thyroid Carcinoma 2 0.039 1.2
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.1